RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2001; 85(05): 932-934
DOI: 10.1055/s-0037-1615771
DOI: 10.1055/s-0037-1615771
Letters to the Editor
Rebuttal to: Oral Contraceptives and Venous Thromboembolism
Authors
Weitere Informationen
Publikationsverlauf
Received
16. November 2001
Accepted
22. Dezember 2000
Publikationsdatum:
11. Dezember 2017 (online)
-
References
- 1 Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives. Thromb Haemost 2000; 84: 1-3.
- 2 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.. Effects of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
- 3 Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 2133-4.
- 4 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third generation oestrogens. Lancet 1995; 346: 1593-6.
- 5 Jick H, Jick SS, Gurewich V, Myers MW, Vasilikis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
- 6 Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and Health of Young Women. Brit Med J 1996; 312: 83-8.
- 7 Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
- 8 Mellemkjaer L, Sorensen HT, Dreyer L, Olsen J, Olsen JH. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark 1977-95. Brit Med J 1999; 319: 820-1.
- 9 Rosing J, Tans G, Nicolaes GAF, Thomassen MCGLD, van Oerle R, van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Brit J Haematol 1997; 97: 233-8.
- 10 Rosing J, Middeldorp S, Curvers J, Thomassen MCCGD, Nicolaes GAF, Meijers JCM, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
- 11 Tans G, Rosendaal FR, Curvers J, Thomassen MCLGD, Bertina RM, Vandenbroucke JP. APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999; 640: 202-3.
- 12 Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BM, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of Levonorgestrel- and Desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
- 13 Meijers JCM, Middeldorp S, Tekelenberg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.
- 14 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BM, Buller HR, Rosing J. A randomized cross-over study on the efects of Levonorgestrel- and Desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
- 15 Heinemann LAJ, Assman A, Spannag M, Schramm W, Dick A, Kluft C, de Maat MPM. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998; 58: 321-2.
- 16 Skegg DCG. Third generation oral contraceptives. Caution is still justified. Brit Med J 2000; 321: 190-1.
- 17 Farley TMM, Meirik M, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721-35.
- 18 Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risks of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
- 19 Farmer RDT, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. Brit Med J 2000; 321: 477-9.
- 20 Walker AM. Backsliding into correlations. BMJ. http://www.bmj.com/cgieletters/321/7529/477
- 21 Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Competing interests and controversy about third generation oral contraceptives. Brit Med J 2000; 320: 381-2.